Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-10-30 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
AZN CHINA PRESIDENT UNDER INVESTIGATION
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content is an announcement about the investigation of the China President of AstraZeneca. The document is short (2878 characters) and primarily serves as a regulatory announcement rather than a detailed financial report or management discussion. It does not contain financial statements, audit information, or detailed management commentary. It is not an earnings release, annual report, or interim report. It is also not a proxy, voting result, or capital change announcement. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant corporate event (investigation of a senior executive) without fitting into more specific categories.
2024-10-30 English
AZN China President under investigation
Legal Proceedings Report Classification · 99% confidence The document is identified by the header 'RNS Number : 2704K' and contains information disseminated via 'RNS, the news service of the London Stock Exchange.' The content reports on a significant internal event: the investigation of the AstraZeneca China President. This type of material—a timely, material announcement to the market that does not fit into specific financial reporting categories (like 10-K, ER, or DIV)—is typically classified as a general regulatory announcement or filing. Since RNS is explicitly mentioned as the distribution service and the content is a material, non-financial-specific update, the most appropriate category is Regulatory Filings (RNS). It is not a specific legal report (LTR), management change (MANG), or earnings release (ER).
2024-10-30 English
SC 13G
Major Shareholding Notification
2024-10-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The content primarily announces the recommendation for approval of a drug (Wainzua) by the European Medicines Agency's CHMP, including clinical trial results and regulatory status updates. There are no financial statements or detailed financial performance data included. The document is a regulatory announcement of material information rather than a full financial report or earnings release. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-10-21 English
Wainzua recommended for approval in the EU
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 8568I' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved as a Primary Information Provider. The content is a press release announcing a positive recommendation for marketing authorization by the CHMP (Committee for Medicinal Products for Human Use) in the EU for a drug (Wainzua). This type of announcement, which disseminates material, non-public information via an official regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Given the source identifier (RNS Number) and the nature of the release, RNS is the most appropriate classification.
2024-10-21 English
SC 13G
Major Shareholding Notification
2024-10-11 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.